May 30, 2019. Thousands of adverse events associated with surgical staplers had been hidden from patients and physicians prior to the March 2019 Kaiser Health News expose. Such devices must be better regulated and monitored.
Read More »On Medical Treatments & Products
NCHR Testimony at FDA at the Onolcogy Drugs Advisory Committee Meeting on Quizartinib
May 14, 2019. We need new treatments for this deadly disease, but we need to know if a new drug is BETTER than existing treatments. The fact that Quizartinib is quite similar in risks and benefits to chemo, which is not very effective and provides a poor quality of life, is not a good reason to approve this drug.
Read More »NCHR Comments on Responsible Innovation in Dietary Supplements
May 16, 2019. The dietary supplement industry has made substantial progress in
weeding out bad actors since the “wild, wild West”, largely unregulated days of the mid-
1990’s. We support FDA’s recent efforts to crack down on manufacturers who make false or
misleading claims about their dietary supplements.
NCHR Testimony on Mannitol Inhalation Powder for Cystic Fibrosis
May 9, 2018. It is uncertain if the benefits outweigh the risks based on the data discussed today. However, there should be sufficient evidence of both safety and efficacy before approval.
Read More »NCHR Report: The Health Risks of MRIs with Gadolinium-Based Contrast Agents
Gadolinium-based contrast agents can improve the diagnostic accuracy of MRIs, however gadolinium can stay in the body for months or years. There are many unanswered questions about who develops health problems related to gadolinium, how to determine if symptoms are due to gadolinium, and how to prevent or treat gadolinium-related conditions.
Read More »